Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Developed by Novo Nordisk, WEGOVY (semaglutide) is a GLP-1 receptor agonist designed to support sustainable weight loss when paired with a balanced diet and regular physical activity
Over a median follow-up of 49.5 months, the risk for MACE was significantly lower in the oral semaglutide compared with the placebo group (HR 0.86
CAUTION: Formulated for adults and children four years and older
Weight loss results vary significantly by specific medication and dose: Semaglutide 2.4 mg (Wegovy): Clinical trials (STEP program) showed average weight reductions of 1517% at 68 weeks Tirzepatide (Zepbound): SURMOUNT trials demonstrated weight reductions of 1522% at 72 weeks, with results varying between populations with and without diabetes Liraglutide 3 mg (Saxenda): Typically produces 510% weight loss over 56 weeks The rate of weight loss is not linear
2020 May 20
US$ 29.13
US$ 21.36
US$ 21.37
US$ 27.08
US$ 22.76
US$ 28.70
